Quanterix Corporation has issued an amendment to its Current Report (Form 8-K/A) following the completion of a merger with Akoya Biosciences, Inc. on July 8, 2025. The amendment provides unaudited pro forma condensed combined financial information, reclassifying certain financial items to align with Quanterix's presentation. These adjustments include reclassifications of interest expense, amortization of capitalized software costs, and changes in the fair value of contingent consideration. The report clarifies that the pro forma data is not necessarily indicative of actual or future financial outcomes.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quanterix Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001503274-25-000095), on September 23, 2025, and is solely responsible for the information contained therein.